BioStem Technologies, Inc.

NASDAQ:BSEM

Biotechnology

Healthcare
$3.07 -6.54%

-$0.21 today

Market cap
$52.14M
Beta
0.26
P/E (TTM)
-1.8
EPS (TTM)
-$1.63
52W Low $2.25High $8.40

Volume 0.09M

Average 0.07M

BSEM Selling, General & Admin

Overhead costs of running the business, including sales, marketing, management, and administrative staff.

BioStem Technologies, Inc.NASDAQ: BSEM

Selling, General & Admin · Q2 FY2026 · quarter ended Jun 2026

Selling, general & admin declines year over year

Q2 FY2026 selling, general & admin of $11.82M fell 74.6% year over year, ahead of the -118.8% change in trailing-twelve-month selling, general & admin. Sequentially, it rose 7.8% from the prior quarter. Over 3 fiscal years it compounded at +54.7% a year.

Context

  • Selling, general & admin amounted to 79.7% of revenue in FY2025, down 4.7 pp from a year earlier.
  • Selling, general & admin increased in 2 of the last 3 fiscal years.

What to watch

Whether selling, general & admin reaches the consensus estimate from 1 analysts of $31.3M (-17.2%) for the fiscal year ending Dec 2026, a step up from the -85.2% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterJun 2026
$11.82M+7.8% QoQ
Last fiscal yearDec 2025
$37.82M-85.2% YoY
LTMJun 2026
-$50.55M-118.8% YoY
Selling, General & Admin past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-74.6%+34.5%+109.1 pp
1 year-85.2%-17.2%+67.9 pp
3-year CAGR+54.7%+34.7%-20.1 pp
5-year CAGR+26.9%—
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Selling, General & Admin history

USD · from the income statement

Latest · FY2025
37.82M USD
Year-over-year change
-85.2%
4-year CAGR
+73.4%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Selling, General & Admin vs competitors

How BSEM compares with its peers on the latest reported figures

No competitor Selling, General & Admin figures are available to compare.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue4.34M6.88M16.69M301.83M47.48M
Cost of Revenue1.47M881.75K1.26M13.75M3.26M
Gross Profit2.87M5.99M15.42M287.86M44.22M
Gross Margin66.0%87.2%92.4%95.4%93.1%
Research & Development119.65K123.31K342K1.91M7.09M
Selling, General & Admin4.19M10.21M22.63M254.75M37.82M
Operating Expenses4.47M10.67M23.2M256.66M44.91M
Depreciation & Amortization283.9K243.42K229.02K293.22K219.42K
EBITDA(602K)(6.52M)(7.55M)31.49M(469.73K)
EBITDA Margin-13.9%-94.8%-45.3%10.4%-1.0%
Operating Income(1.61M)(4.68M)(7.78M)31.2M(689.15K)
Operating Margin-37.0%-68.1%-46.6%10.3%-1.5%
Interest Income0000413.85K
Interest Expense525.88K468.15K700.33K587.22K0
Other Income / Expenses193.93K(2.55M)(704.02K)(587.22K)299.5K
Income Before Tax(1.41M)(7.11M)(8.48M)30.61M(389.65K)
Pre-Tax Margin-32.5%-103.5%-50.8%10.1%-0.8%
Income Tax Expense000(1.27M)6.19M
Net Income(1.45M)(7.07M)(8.48M)31.88M(6.58M)
Net Margin-33.3%-102.9%-50.8%10.6%-13.9%
EPS (Basic)(0.12)(0.62)(0.62)1.95(0.39)
EPS (Diluted)(0.12)(0.62)(0.62)1.47(0.39)
Weighted Avg Shares11.69M11.41M13.71M16.37M16.73M
Weighted Avg Shares (Diluted)11.69M11.41M13.71M21.7M16.73M

BioStem Technologies, Inc.

NASDAQ:BSEM

Intrinsic Alpha fair value

Locked

Current Price

$3.07

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.